Transplant Ineligible Multiple Myeloma: Updates to the MAIA Study

home / investigator-perspectives / transplant-ineligible-multiple-myeloma-updates-to-the-maia-study

Considerations for updated data from the MAIA study of daratumumab plus lenalidomide and dexamethasone, and how they fit into the optimal management of transplant-ineligible newly diagnosed multiple myeloma.